Form 4 for CBIO CRESCENT BIOPHARMA, INC.
Accepted 2023-09-25 00:00:00 ET · period of report 2023-09-21 · accession 0001209191-23-050476 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2023-09-25 | 2023-09-21+ | CBIO | Rock Edwin | Chief Medical Off | P - Purchase | $1.38 | +65.4K | 345.0K | +23% | +$90.3K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-09-22 | P | A | 30,403 | $1.38 | 375,403 | D | — | — | (F2) The Reporting Person purchased the securities on the open market at purchase prices ranging from $1.37 to $1.40 per share, with a weighted average purchase price of $1.38 per share. The Reporting Person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price. |
| 2 | Common | Common Stock | 2023-09-21 | P | A | 35,000 | $1.38 | 345,000 | D | — | — | (F1) The Reporting Person purchased the securities on the open market at purchase prices ranging from $1.35 to $1.40 per share, with a weighted average purchase price of $1.38 per share. The Reporting Person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price. |